clinical trial · NCT02719613
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb·phase2·completed·n = 67
Multiple MyelomaElotuzumabDexamethasoneDexamethasoneLenalidomideBortezomibPomalidomideNivolumab
brief summary
The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.
started
Jul 15, 2016
primary completion
Feb 23, 2026
completion
Feb 23, 2026
last updated
Apr 15, 2026
official title
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol